Irinotecan: Phase I started

Merrimack began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV MM-398 plus IV cyclophosphamide in about 40 patients ages 1-20 years with recurrent or refractory solid tumors. MM-398...